Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | GALR1 | P47211 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21509882 | 0.85 | ROCK2 (0.60) | ROCK2MAOAMAOB | |
| SCHEMBL24076596 | 0.81 | ROCK2 (0.56) | ROCK2 | |
| SCHEMBL4114637 | 0.79 | BRAF (0.61) | NPC1BRAFHSD17B2 | |
| SCHEMBL29617015 | 0.75 | TP53 (0.62) | NPC1GALR1 | |
| SCHEMBL4193217 | 0.74 | TP53 (0.61) | GALR1 | |
| SCHEMBL12553322 | 0.74 | NPC1 (0.57) | NPC1BRAFHSD17B2GALR1 | |
| SCHEMBL1144543 | 0.74 | MEN1 (0.44) | PDGFRBPDGFRAHSD17B2 | |
| SCHEMBL4174579 | 0.73 | CYP1A1 (0.54) | GALR1 | |
| SCHEMBL12581547 | 0.73 | NPC1 (0.56) | NPC1BRAFHSD17B2 | |
| SCHEMBL2404818 | 0.71 | NPC1 (0.59) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | ROCK1, ROCK2, CIT | ROCK2 2/4885NPC1 1096/4885BRAF 305/4885 |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | ROCK2 2/4885NPC1 1096/4885BRAF 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.